Kedar Kirtane, MD
Hematology & Oncology · Tampa, FLNPI 1861767014
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,763 of the $2,012 with a category attached, or 87.6%. Janssen Scientific Affairs, LLC accounts for 87.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $1,851, more than ten times the $135 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 4 payments — averaging $503.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$2K
- GE HealthCare$135
- Fennec Pharmaceuticals, Inc.$88
- Coherus Oncology, Inc.$27
Across 108 payments — averaging $7212.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$665K
- Modernatx, Inc.$114K
What the payments were for
- Consulting fees$1,76388%
- Food & beverage$25012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $1,763 |
| GE HealthCare | 1 | $135 |
| Fennec Pharmaceuticals, Inc. | 1 | $88 |
| Coherus Oncology, Inc. | 1 | $27 |
How this compares
$2,012 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 22 | $507,545 |
| TafinlarDabrafenib Mesylate | 12 | $172,275 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $164,868 |
| RetevmoSelpercatinib | 11 | $127,424 |
| Xtampza ErOxycodone Myristate | 11 | $10,950 |
| EliquisApixaban | 14 | $8,304 |
| Levothyroxine Sodium | 48 | $570 |
| Oxycodone Hcl | 32 | $356 |
| Prochlorperazine Maleate | 12 | $215 |
| Lorazepam | 33 | $197 |
| Losartan Potassium | 11 | $136 |
| Prednisone | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.